There are currently 5 active clinical trials seeking participants for SARS-CoV-2 research studies. The states with the highest number of trials for SARS-CoV-2 participants are Texas, Florida, California and New York.
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
NCT05876377
Recruiting
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions. to understand characteristics of patients who are receiving COVID-19 vaccines. All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.
Gender:
All
Ages:
6 months and above
Trial Updated:
05/31/2024
Locations: Pfizer, New York, New York
Conditions: SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age
NCT05436834
Recruiting
This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to <6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a single booster dose (BD) given to participants who previously received 2 doses of the mRNA-1273 vaccine as a primary series (Part 2); and will evaluate the safety and immunogenicity of th... Read More
Gender:
All
Ages:
Between 6 months and 5 years
Trial Updated:
05/24/2024
Locations: Trinity Clinical Research, LLC, Bessemer, Alabama +48 locations
Conditions: SARS-CoV-2
Register for Updates
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
NCT05954286
Recruiting
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/07/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland +4 locations
Conditions: SARS-CoV-2
Register for Updates
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
NCT05584202
Recruiting
The study will evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
Gender:
All
Ages:
Between 2 months and 6 months
Trial Updated:
03/12/2024
Locations: Trinity Clinical Research, LLC - Bessemer, Bessemer, Alabama +50 locations
Conditions: SARS-CoV-2
Register for Updates
Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment
NCT04918914
Recruiting
Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3). Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor. Methods: Patients who were... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/07/2021
Locations: Hunt Regional Medical Center, Greenville, Texas
Conditions: SARS-CoV-2, Hypoxia, ARDS
Register for Updates